Literature DB >> 16214015

Bacterial detection of platelets: current problems and possible resolutions.

Morris A Blajchman1, Erik A M Beckers, Ebbe Dickmeiss, Lilly Lin, Gillian Moore, Ludo Muylle.   

Abstract

The greatest transfusion-transmitted disease risk facing a transfusion recipient is that of bacterial sepsis. The prevalence of bacterial contamination in platelets and red blood cells is approximately 1 in 3,000 units transfused. The available data indicate that transfusion-associated sepsis develops after 1 in 25,000 platelet transfusions and 1 in 250,000 red blood cell transfusions. One of the most widely used strategies for decreasing bacterial sepsis risk is bacterial detection. A roundtable meeting of experts was convened during the XXVIII Annual Congress of the International Society of Blood Transfusion (Edinburgh, UK, July 2004) to provide a forum for experts to share their experiences in the routine bacterial detection of platelet products. This article summarizes the presentations, discussions, and recommendations of the panel. The data presented indicate that some of the current bacterial screening technology is useful for blocking the issuance of platelet units that contain relatively high levels of contaminating bacteria. Platelet units are usually released based on a test-negative status, which often become test-positive only upon longer storage. These data thus suggest that bacterial screening may not prevent all transfusion-transmitted bacterial infections. Two transfusion-transmitted case reports further highlighted the limitation of the routine bacterial screening of platelet products. It was felt that newer technologies, such as pathogen inactivation, may represent a more reliable process, with a higher level of safety. The panel thus recommended that the Transfusion Medicine community may need to change its thinking (paradigm) about bacterial detection, toward the possibility of the pathogen inactivation of blood products, to deal with the bacterial contamination issue. It was suggested, where permitted by regulatory agencies, that blood centers should consider adopting first-generation pathogen inactivation systems as a more effective approach to reducing the risk of transfusion-associated sepsis than some of the approaches currently available.

Entities:  

Mesh:

Year:  2005        PMID: 16214015     DOI: 10.1016/j.tmrv.2005.05.002

Source DB:  PubMed          Journal:  Transfus Med Rev        ISSN: 0887-7963


  17 in total

Review 1.  Reduction of the risk of bacterial contamination of blood components through diversion of the first part of the donation of blood and blood components.

Authors:  Giancarlo Maria Liumbruno; Liviana Catalano; Vanessa Piccinini; Simonetta Pupella; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2009-04       Impact factor: 3.443

2.  Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma.

Authors:  Giancarlo Maria Liumbruno; Maria Laura Sodini; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2008-01       Impact factor: 3.443

Review 3.  Cell-derived microparticles in stored blood products: innocent-bystanders or effective mediators of post-transfusion reactions?

Authors:  Anastasios Kriebardis; Marianna Antonelou; Konstantinos Stamoulis; Issidora Papassideri
Journal:  Blood Transfus       Date:  2012-05       Impact factor: 3.443

4.  [Conventional vs pathogen-inactivated platelet concentrates for the treatment of perioperative coagulopathy. A prospective cohort study].

Authors:  C F Weber; D Meininger; C Byhahn; E Seifried; K Zacharowski; E Adam; R Henschler; M M Müller
Journal:  Chirurg       Date:  2011-04       Impact factor: 0.955

5.  Bordetella holmesii Contamination of Platelet Concentrates: Revisiting the Definition of a Positive Culture.

Authors:  Gilles Delage; Louis Thibault; Marc Cloutier; Marie-Ève Nolin; Hana Daoud; Annie Jacques; Marie Joëlle de Grandmont; Éric Ducas
Journal:  J Clin Microbiol       Date:  2018-11-27       Impact factor: 5.948

6.  Hemostatic efficacy of pathogen-reduced platelets in children undergoing cardiopulmonary bypass.

Authors:  Sophia Hsien; Jeffrey D Dayton; Dennis Chen; Arabella Stock; Emile Bacha; Melissa M Cushing; Marianne E Nellis
Journal:  Transfusion       Date:  2021-12-13       Impact factor: 3.157

7.  Enhanced shear-induced platelet aggregation due to low-temperature storage.

Authors:  Robbie K Montgomery; Kristin M Reddoch; Shankar J Evani; Andrew P Cap; Anand K Ramasubramanian
Journal:  Transfusion       Date:  2012-10-09       Impact factor: 3.157

8.  From the donor's arm to blood product: a study on bacterial contamination of apheresis platelet concentrates.

Authors:  Anna Maria Leo; Maria Monica Salvadego; Maria Grazia Piva; Graziano Ruffato; Sara Valverde; Ernesto Trabuio; Francesco Antico; Gianluca Gessoni
Journal:  Blood Transfus       Date:  2007-07       Impact factor: 3.443

9.  Nationwide Implementation of Pathogen Inactivation for All Platelet Concentrates in Switzerland.

Authors:  Markus Jutzi; Behrouz Mansouri Taleghani; Morven Rueesch; Lorenz Amsler; Andreas Buser
Journal:  Transfus Med Hemother       Date:  2018-05-23       Impact factor: 3.747

10.  Platelet Septic Transfusion Reactions in Patients With Hemato-Oncological Diseases.

Authors:  Farhad Razjou; Abolfazl Dabir Moghaddam; Gharib Karimi; Maryam Zadsar
Journal:  Iran J Pathol       Date:  2017-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.